New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX From The Last 14 Days
Check below for free stories on A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
September 2, 2014
07:21 EDTSNYRegeneron data positive, says RBC Capital
Subscribe for More Information
August 31, 2014
14:22 EDTSNYSanofi, Regeneron announce results from four Phase 3 ODYSSEY trials
Subscribe for More Information
14:18 EDTBSXBoston Scientific NECTAR-HF trial did not meet primary efficacy endpoint
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure, NECTAR-HF, clinical trial, the first and only randomized sham-controlled clinical trial investigating vagus nerve stimulation, VNS, for the treatment of heart failure patients. Faiez Zannad, M.D., Ph.D., Professor of Therapeutics and Cardiology and Director of the Clinical Investigation Center at the Institut National de la Sante et de la Recherche Medicale presented the results at the 2014 European Society of Cardiology Congress in Barcelona, Spain. The results will also be published in the European Heart Journal. The study evaluated 96 New York Heart Association,NYHA, Class II-III patients with heart failure and an ejection fraction of less than 35%. All patients continued receiving optimal medical treatment for heart failure, but were randomized 2:1 to treatment or sham, respectively. The trial did not meet the pre-specified six month primary efficacy endpoint of a reduction in left ventricular end systolic diameter as assessed by a blinded echocardiography core laboratory. Quality of life metrics demonstrated significant symptomatic improvement despite the lack of a significant effect on primary and secondary endpoint measures of cardiac remodeling and functional capacity in HF patients. "The careful design and execution of NECTAR-HF has resulted in high quality data that will improve the understanding of the role of VNS in the treatment of patients with heart failure," said Prof. Zannad, NECTAR-HF Principal Investigator. "Although patients receiving therapy reported feeling better as assessed by quality of life questionnaires, the application of VNS failed to reveal clear benefit when compared to sham, because the effect of therapy was no better than sham on echocardiography derived measurements. Inclusion of an appropriate control group is crucial, and a randomized study like NECTAR-HF should be the benchmark for future studies of novel device therapies for the treatment of heart failure." After six months of randomization, control patients begin to receive active therapy. All patients are followed through 18 months for the safety endpoint.
12:50 EDTSNYEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 29, 2014
17:06 EDTBSXBoston Scientific reports results from multinational stent study
A Boston Scientific prospective, multinational study on stent removability and preliminary long term stricture resolution of benign biliary strictures has been published in the August issue of the peer-reviewed journal, Gastroenterology. The multinational study is being conducted in 11 countries and five continents, and examines removal of fully covered self-expanding metal stents after extended indwell. The 187-patient study was designed to evaluate the ability to remove the Fully Covered WallFlex Biliary RX Stent after extended indwell and to determine treatment success of biliary obstructions resulting from benign biliary strictures. Data highlights: The WallFlex Biliary RX Stents were successfully removed by endoscopy from all 155 patients in whom this procedure was attempted. Stricture resolution without the need to restent at the time of stent removal was successful in approximately 75% of patients. Approximately 85% of these patients remained stricture-free after a mean follow-up of 20 months. The study results demonstrate that FCSEMS are an effective treatment alternative to plastic stents, and may significantly reduce the need for multiple sequential Endoscopic Retrograde Cholangiopancreatogram stent exchanges and the associated complications and costs.
12:23 EDTSNYNovartis drug data to be presented this weekend
Subscribe for More Information
10:06 EDTSNYSanofi unit treatment of Fabry's disease granted orphan status
Subscribe for More Information
08:18 EDTSNYPerrigo among companies showing interest in Omega Pharma, Bloomberg says
Subscribe for More Information
August 28, 2014
17:42 EDTBSXJ&J begins sales process for its medical device unit Cordis, WSJ says
Subscribe for More Information
August 27, 2014
08:33 EDTCVSCVS Caremark announces new clinical affiliation with MedStar Health
Subscribe for More Information
08:03 EDTTERTeradynes design win at ZTE an incremental positive, says Goldman
Subscribe for More Information
08:00 EDTTERZTE adopts LifePoint Solutions for LTE smartphone production test
Subscribe for More Information
August 25, 2014
12:19 EDTSNYOn The Fly: Midday Wrap
Subscribe for More Information
11:48 EDTSNYSanofi and Regeneron co-host a conference call
Subscribe for More Information
11:09 EDTBSXFDA confirms third Watchman panel for Boston Scientific, says Wells Fargo
Subscribe for More Information
10:40 EDTSNYBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
August 24, 2014
21:53 EDTCVSNational Association of Chain Drug Stores to hold an expo
2014 NACDS Total Store Expo to be held in Boston on August 23-25.
August 22, 2014
12:39 EDTSNYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
05:31 EDTTERStocks with implied volatility movement; EBAY TER
Subscribe for More Information
August 21, 2014
10:34 EDTTEROptions Update; August 21, 2014
Subscribe for More Information
10:20 EDTTERHigh option volume stocks
Subscribe for More Information
05:42 EDTSNYIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 19, 2014
16:46 EDTSNYFDA approves Genzyme Cerdelga capsules
Subscribe for More Information
08:42 EDTRRyder shares expected to trade to $117 in 12 months at FBR Capital
Subscribe for More Information
05:14 EDTBSXBoston Scientific, ASAHI INTECC announce joint development programs
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use